TG Therapeutics Inc

22 sie 2026, 00:02 UTC

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

21 sie 2026, 23:01 UTC

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

20 sie 2026, 21:01 UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

19 sie 2026, 19:27 UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

17 sie 2026, 19:56 UTC

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

14 sie 2026, 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13 sie 2026, 20:02 UTC

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10 sie 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7 sie 2026, 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6 sie 2026, 20:03 UTC

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5 sie 2026, 19:56 UTC

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4 sie 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3 sie 2026, 23:06 UTC

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31 lip 2026, 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 lip 2026, 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 lip 2026, 15:52 UTC

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 lip 2026, 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 lip 2026, 19:07 UTC

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 lip 2026, 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 lip 2026, 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22 lip 2026, 23:31 UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21 lip 2026, 22:21 UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20 lip 2026, 23:22 UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.